The persistent inability to find a JV partner has to be a...

The persistent inability to find a JV partner has to be a concern.  All the recent study announcements have been predictable when you look at those from 1-2 years ago.  It's clear that there is modest anti-HCV activity in combination, and it's not (very) toxic.  Why is nobody interested still?  Why when I sit through HCV treatment summary presentations by the world's opinion leaders does nobody ever mention Biotron?  A big problem as I see it is that this company is grossly underfunded.  It is doing terribly drawn out trials answering yesterday's questions, and when raising money it is only raising enough to do move forward slowly and indecisively (and employ more executives!). The only way this company is going to get large companies interested as far as HCV is concerned is with a DAA trial in G3 cirrhotics.  Such a trial is still not on the horizon with this capital raising.